Antiplatelet agents

Pharmacochemistry Library

Volumn 28, Issue C, 1997, Pages 511-535

  Wexler, Ruth R ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957191992     PISSN: 01657208     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0165-7208(97)80091-8     Document Type: Article

References (125)

1. Fuster V., Steele P.M., and Chesebro J.H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll. Cardiol. 5 (1985) 175B-184B
2. Fitzgerald D.J., Roy L., Catella F., and Fitzgerald G.A. Platelet activation in unstable coronary disease. N Engl J Med 315 (1986) 983-989
3. Davies M.J., and Thomas AC. Plaques fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53 (1985) 363-373
4. Leonard E.F., Turitto V.T., and Vroman L. Blood in contact with natural and artificial surfaces. Ann NY Acad Sci 516 (1987) 1-688
5. Rubenstein M.D., Wall R.T., Bain D.S., and Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 102 (1981) 363-367
6. Willerson J.T., Golino P., Eidt J., Campbell W.B., and Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation (1989) 198-205
7. Hamm C.W., Bliefield W., Kupper W., Lorenz R.L., Weber P.C., and Wober W. Biochemical evidence of platelet activation in patients with persistant unstable angina. J Am Coll Cardiol 10 (1987) 998-1004
8. Ashby B., Daniel J.L., and Smith J.B. Mechanisms of platelet activation and inhibition. Platelet in Health & Disease 4 1 (1990) 1-26
9. Fiore L.D., and Deykin D. Use of antiplatelet agents and anticoagulants in post-myocardial infarction. Cardiology Clinics 12 3 (1994) 451-476
10. Schrör K. Antiplatelet Drugs. Drugs 50 1 (1995) 7-28
11. Alimony G.T., Lefkovits J., and Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 19 (1996) 357-365
12. Verstraete M., and Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 49 6 (1995) 856-884
13. Kroll M.H., Harris T.S., Moake J.L., Handin R.I., and Schafer AI. Von Willebrand factor binding to platelet Gp lb initiates signals for platelet activation. J Clin Invest 88 (1991) 1568-1573
14. Kroll M.H., and Schafer A.I. Biochemical mechanisms of platelet activation. Blood 74 (1989) 1181-1185
15. Phillips D.R., Charo I.F., and Parise LV. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71 (1988) 831-843
16. Kieffer N., and Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Ann Rev Cell Biol 6 (1990) 329-357
17. Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Hum Pathol 18 (1987) 111-122
18. Lüscher E.F., and Weber S. The formation of the hemostatic plug. Thromb Haemostasis 70 (1993) 234-237
19. ISIS-2(Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet II (1988) 349-360
20. Antiplatelet Trialists'Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 308 (1994) 81-106
21. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296 (1988) 320-331
22. Roth G.J., Stanford N., and Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72 (1975) 3073-3076
23. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330 (1994) 1287-1294
24. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 263 (1992) F181-F191
25. Roderick P.J., Wilkes H.C., and Meade TW. The gastrointestinal toxicity of aspirin: An overview of randomized controlled trials. Br J Clin Pharmac. 35 (1993) 219-226
26. Wexler R.R. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 325 (1991) 1261-1266
27. Roth G.J., and Calverley D.C. Aspirin platelets and thrombosis: Theory and practice. Blood 83 (1994) 885-898
28. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338 (1991) 1345-1349
29. Defreyn G., Bernat A., Delebasse P., and Maffrand J.-P. Pharmacology of ticlopidine: A review. Sem Thromb Hemost. 15 (1989) 159-166
30. Ito M.K., Smith A.R., and Lee ML. Ticlopidine: A new platelet aggregation inhibitor. Drug Reviews 11 (1992) 603-617
31. Saltiel E., Ward A.T.: A.r.o.i.p., and pharmacokinetic p. and therapeutic efficacy in platelet-dependent disease states. Drugs 34 (1987) 222-262
32. Gent M., Blakely J.A., Easton J.D., Ellis D.J., Hachinski V.C., Harbison J.W., Panak E., Roberts R.S., Sicurella J., and Turpie A.G. The Canadian American Ticlopidine Study (CATS) in thromboembolis stroke. Lancet 1 (1989) 1215-1220
33. Hass W.K., Easton J.D., Adams H.P., Pryse-Phillips W., Molony B.A., Anderson S., and Kamm B. Ticlopidine Aspirin Stroke Study Group,A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321 (1989) 501-507
34. Bergquist D., Almgren B., and Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 10 (1995) 69-76
35. Herbert J.M., Frehel D., Vallee E., Kieffer G., Gouy D., Berger Y., Necciari J., Defreyn G., and Maffrand J.P. Clopidegrel a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Reviews 11 (1993) 180-198
36. Savi P., Herbert J., Pflieger A., Dol F., Delebassee D., Combalbert J., Defreyn G., and Maffrand JP. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 44 (1992) 527-532
37. CAPRIE S.C. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 348 (1996) 1329-1339
38. Pytela R., Pierschbacher M.S., Ginsberg M.H., Plow E.F., and Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: Member of a family of RGD specific adhesion receptors. Science 231 (1986) 1559-1562
39. Phillips D.R., Charo I.F., and Scarborough RM. GPIIb-IIIa: The responsive integrin. Cell 65 (1991) 359-362
40. Cox D., Aoki T., Seki J., Motoyama Y., and Yoshida K. The pharmacology of integrins. Med Res Rev. 14 (1994) 195-228
41. D'Souza S.E., Ginsberg M.H., Burke T.A., and Plow E.F. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its alpha subunit. J Biol Chem. 265 (1990) 3440-3446
42. Ruoslahti E. Integrins. J Clin Invest 87 (1991) 1-5
43. Ginsberg M.H., Xiaoping D., O'Toole T.E., Loftus J.C., and Plow EF. Platelet integrins. Thromb Haemostas 70 (1993) 87-93
44. Ginsberg M.H., Xiaoping D., O'Toole T.E., and Loftus JC. Platelet integrins. Thromb Haemostas 74 1 (1995) 352-359
45. Ruoslahti E., and Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 44 (1986) 517-518
46. Ginsberg M.H., Loftus J.C., and Plow EF. Cytoadhesions integrins and platelets. Thromb Haemostas 59 (1988) 1-6
47. D'Souza S.E., Ginsberg M.H., and Plow EF. Arginyl-glycyl-aspartic acid (RGD) : a cell adhesion motif. Trends Biochem Sci 16 (1991) 246-250
48. Plow E.F., Pierschbacher M.D., Ruoshlati E., Marguerie G., and Ginsberg MH. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 70 (1987) 110-115
49. Doolittle R.F., Watt K.W.K., Cottrell B.A., Strong D.D., and Riley M. The amino acid sequence of the a chain of human fibrinogen. Nature 280 (1979) 464-468
50. Pierschbacher M.D., and Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309 (1984) 30-33
51. Plow E.F., Pierschbacher M.D., Ruoshlati E., Marguerie G.A., and Ginsberg MH. The effect of Arg-Gly-Asp containing peptides on fibrinogen and von Willebrand Factor binding to platelets. Proc Natl Acad Sci USA 82 (1985) 8057-8061
52. Haverstick D.M., Cowan J.F., Yamada K.M., and Santoro S.A. Inhibition of platelet adhesion to fibronectin fibrinogen and von Willebrand Factor substrate by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 66 (1985) 946-952
53. Hawiger J., Timmons S., Kloczewiak M., Strong D.D., and Doolittle RF. γ and α chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Nat'l Acad Sci USA 79 (1982) 20678-20718
54. Kloczewiak M., Timmons S., and Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Throm Res 29 (1983) 249-255
55. Kloczewiak M., Timmons S., Lukas T.J., and Hawiger J. Platelet receptor recognition site on human fibrinogen.Syntheses and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain. Biochemistry 23 (1984) 1767-1774
56. Ojima I., Chakravarty S., and Dong Q. Antithrombotic agents: From RGD to peptide mimetics. Bioorg Med Chem 3 (1995) 337-360
57. Gould R.J. The integrin αIIbβ3 as an antithrombotic target. Perspectives in Drug Discovery and Design 1 (1993) 537-548
58. Weller T., Alig L., Müller M.H., Kouns W.C., and Steiner B. Fibrinogen receptor antagonists -a novel class of promising antithrombotics. Drugs of the Future 19 (1994) 461-476
59. Cook N.S., Kottirsch G., and Zerwes HG. Platelet glycoprotein IIb/IIIa antagonists. Drugs of the Future 19 (1994) 135-159
60. Raddatz P., and Gante J. Recent developments in glycoprotein IIb/IIIa antagonists. Exp Opin Ther Patents 5 (1995) 1165-1183
61. Coller B.S., Anderson K., and Weisman HF. New antiplatelet agents: Platelets GP IIb/IIIa antagonists. Thromb Haemost 74 1 (1995) 302-308
62. Lefkovits J., Plow E.F., and Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Eng J Med 332 23 (1995) 1553-1559
63. Crenshaw B.S., Harrington R.A., and Tcheng JE. Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors. Exp Opin Invest Drugs 4 (1995) 1033-1044
64. Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the glycoprotein IIb/IIIa complex. J Clin Invest 76 (1985) 101-108
65. Coller B.S., Folts J.D., Scudder L.E., and Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68 (1986) 783-786
66. Jordan R.E., Knight D.M., Wagner C., McAleer F., McDonough M., Mattis J.A., Coller B.S., and Weisman H.F. A dramatic reduction of the immunogenicity of the anti-GPIIB-IIIA monoclonal antibody 7E3 FAB by humanization of the murine constant domains. (Abstract). 65th Scientific Sessions of the American Heart Association. New Orleans, LA, November 16-19, 1992. Circulation 86 (1992) I-411 4
67. Coller B.S., Scudder L.E., Beer J., Gold H.K., Folts J.D., Cavagnaro J., Jordan R., Wagner C., Iuliucci J., Knight D., Ghrayeb J., Smith C., Weisman H.F., and Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 614 (1991) 193-213
68. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
69. Califf R.M., Lincoff A.M., Tcheng J.E., and Topol E.J. An overview of the results of the EPIC trial. Eur Heart J 16 suppl. L (1995) 43-49
70. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., Weston M., Sigmon K., Anderson K.M., Lee K.L., and Willerson J.T. On behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The Lancet 343 (1994) 881-886
71. Ferguson III J.J. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 93 (1996) 637
72. (Editorial). Van d.W., and F. M. evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-Blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 17 (1996) 325-326
73. Gould R.J., Polokoff M.A., Friedman P.A., Huang T.-F., Holt J.C., Cook J.T., and Niewiaroski S. Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 195 (1990) 168-171
74. Scarborough R.M., Rose J.W., Hsu M.A., Phillips D.R., Fried V.A., Campbell A.M., Nannizzi L., and Charo IF. Barbourin: A GPIIb-IIIa-specific integrin antagonist from the venon of Sistrurus M barbouri. J Biol Chem 266 (1991) 9359-9362
75. Scarborough R.M., Naughton M.A., Teng W., Rose J.W., Phillips D.R., Nannizzi L., Arfsten A., Campbell A.M., and Charo IF. Design of potent and specific integrin antagonists. J Biol Chem 268 (1993) 1066-1073
76. (Abstract). Charo I.F., Scarborough R.M., Du M.C., Wolf D., Phillips D.R., and Swift RL. Pharmacodynamics of the GPIIb-IIIa antagonist integrelin: Phase I clinical studies in normal healthy volunteers. Circulation 86 suppl. I (1992) I-260
77. (Abstract). Schulman S.P., Goldschmidt-Clermont P.J., Navetta F.I., Chandra N.C., Guerci A.D., Califf R.M., Ferguson J.J., Willerson J.T., Wolfe C.L., Bahr R., Yakubov S.J., Nygaard T.M., Mason S.J., Brashears L., Charo I., du M.C., Kitt M.M., and Gerstenblith G. Integrelin in unstable angina: A double-blind randomized trial. Circulation 88 (1993) I-608
78. (Abstract). Harrington R.A., Schulman S.P., Kleiman N.S., Lincoff A.M., Goldschmidt-Clermont P.J., Joseph D., Sigmon K.N., Parker J., Marchant K., and Kitt M.M. Profound sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation 90 (1994) I-232
79. Tcheng J.E., and Lincoff A.M. IMPACT-II results. Presented at the XVIIth Congress of the European Society of Cardiology (Hotline session). The Netherlands, Amsterdam, August 20-24 (1995)
80. (2 suppl. A). Horrigan M.C., Tcheng J.E., Califf R.M., Kitt M., Lorenz T., Sigmon K., Lincoff A.M., and Topol E.J. Maximal benefit of integrelin platelet GP IIb-IIIa blockade 6-24 hours after therapy: results of the IMPACT-II trial. 45th Annual Scientific Session of the American College of Cardiology. Orlando, Florida, March 24-27, 1996. J Amer Coll Cardiol 27 (1996) 536-542
81. Egbertson M.S., Chang C.-T., Duggan M.E., Gould R.J., Halczenko W., Hartman G.D., Laswell W.L., Lynch Jr. J.J., Lynch R.J., Manno P.D., Naylor A.M., Prugh J.D., Ramjit D.R., Sitko G.R., Smith R.S., Turchi L.M., and Zhang G. Non-peptide fibrinogen receptor antagonists. 2.Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 37 (1994) 2537-2551
82. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., Naylor A.M., Manno P.D., Lynch R.J., Zhang G., Chang C.-T., and Gould R.J. Non-peptide fibrinogen receptor antagonists. 1.Discovery and design of exosite inhibitors. J Med Chem 35 (1992) 4640-4642
83. Peerlink K., DeLepeleire I., Goldberg M., Farrell B.A., Barrett J., Hand E., Panebianco D., Deckmyn H., Vermylen J., and Arnout J. MK-383 (L-700462)a selective non peptide platelet glycoprotein IIb/IIIa antagonist is active in man. Circulation 88 (1993) 1512-1517
84. Barrett J.S., Murphy M.G., Peerlink K., DeLepeleire I., Gould R.J., Panebianco D., Hand E., Deckmyn H., Vermylen J., and Arnout J. Pharmacokinetics pharmacodynamics^of MK-383 a selectivenon-peptide^platelet glyco-protein-IIb/IIIa receptor antagonistin healthy men. Clin Pharmacol Ther 56 (1994) 277-388
85. Kereiakes D.J., Kleiman N.S., Ambrose J., Cohen M., Rodriguez S., Palabrica T., Herrmann H.C., Sutton J.M., Weaver D., McKee D.B., Fitzpatrick V., and Sax FL. Randomized double-blind placebo-controlled dose-ranging study of Tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 27 (1996) 536-542
86. Alig L., Edenhofer A., Hadváry P., Hürzeler M., Knopp D., Müller M., Steiner B., Trzeciak A., and Weller T. Low molecular weight non-peptide fibrinogen receptor antagonists. J Med Chem 35 (1992) 4393-4407
87. (Abstract 860). Steiner B., Haring P., Jennings L., and Kouns WC. Five independent neo-epitopes on GPIIb-IIIa are differentially exposed by two potent peptido-mimetic platelet inhibitors. Throm Haem 69 (1993) 782
88. Lave T., Saner A., Coassolo P., Brandt R., Schmitt-Hoffman A., and Chou R.C. Animal pharmacokinetics interspecies^scaling from animals to man of Lamifiban a new platelet aggregation inhibitor. J Pharm Pharmacol 48 (1996) 573-577
89. (Abstract). Théroux P., Kouz S., Knudtson M.L., Kells C., Nasmith J., Roy L., Dalle A.S., Steiner B., Xiao Z., and Rapold H.J. A randomized double-blind controlled trial with the non-peptide platelet GPIIb/IIIa antagonist Ro 44-9883 in unstable angina. Circulation 90 (1994) 1-232
90. Moliterno D.J., Harrington R.A., Califf R.M., Rapold H.J., and Topol EJ.R. placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) study. J Thromb Thrombolysis 2 (1995) 165-169
91. Zablocki J.A., Miyano M., Garland R.B., Pireh D., Schretzman L., Rao S.N., Lindmark R.J., Panzer-Knodle S.G., Nicholson N.S., Taite B.B., Salyers A.K., King L.W., Campion J.G., and Feigen LP. Potent in vitro in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb/IIIa receptor.A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb/IIIa receptor.A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb/IIIa receptor. J Med Chem 36 13 (1993) 1811-1819
92. Zablocki J.A., Rico J.G., Garland R.B., Rogers T.E., Williams K., Schretzman L.A., Rao S.A., Bovy P.R., Tjoeng F.S., Lindmark R.J., Tóth M.V., Zupec M.E., McMackins D.E., Adams S.P., Miyano M., Markos C.S., Milton M.N., Paulson S., Herin M., Jacqmin P., Nicholson N.S., Panzer-Knodle S.G., Haas N.F., Page J.D., Szalony J.A., Taite B.B., Salyers A.K., King L.W., Campion J.G., and Feigen LP. Potent in vitro in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino) succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J Med Chem 38 (1995) 2378-2394
93. Nicholson N.S., Panzer-Knodle S.G., Salyers A.K., Taite B.B., Szalony J.A., Haas N.S., King L.W., Zablocki J.A., Keller B.T., Broschat K., Engleman V.W., Herin M., Jacqmin P., and Feigen LP. SC-54684A: An orally active inhibitor of platelet aggregation. Circulation 91 (1995) 403-410
94. Szalony J.A., Haas N.F., Salyers A.K., Taite B.B., Nicholson N.S., Mehrotra D.V., and Feigen LP. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 91 (1995) 411-416
95. (Abstract). Anders R.J., Alexander J.C., Hantsbarger G.L., Burns D.M., Oliver S.D., Cole G., and Fitzgerald D.J. Demonstration of potent inhibition of platelet aggregation with an orally active GPIIb/IIIa receptor antagonist. J Am Coll Cardiol 25 (1995) 117A
96. Bach I.A., Eyermann C.J., Gross J.D., Bower M.J., Harlow R.L., Weber P.C., and DeGrado WF. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J Am Chem Soc 116 (1994) 3207-3219
97. Jackson S., DeGrado W.F., Dwivedi A., Parthasarathy A., Higley A., Krywko J., Rockwell A., Markwalder J., Wells G., Wexler R.R., Mousa S., and Harlow R. Template-constrained cyclic peptides: Design of high-affinity ligands for GPIIb/IIIa. J Am Chem Soc 116 (1994) 3220-3230
98. Wityak J, Sielecki TM, Pinto DJ, Sze JY, Liu J, Tobin AE, Wang S, Jiang B, Emmett G, Ma P, Mousa SA, Olson RE, Wexler RR. The discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists. J Med Chem (in press).
99. MEDI 250. Olson R.E., Wityak J., Xue C.-B., Sielecki T.M., Cain G.A., Mousa S.A., Thoolen M.J., Racanelli A.L., Hausner E.A., Reilly T.M., DeGrado W.F., and Wexler R.R. The discovery of DMP 754, an orally active isoxazoline GPIIb/IIIa antagonist. 211 ACS Meeting. New Orleans, USA (1996)
100. MEDI 1132. Xue C.-B., Wityak J., Sielecki T.M., Cain G.A., Liu J., Bostrom L.L., Di M.S., Higley C.A., Lalka G.K., Tobin A.E., Frietze W.E., Emmett G., Sze J.Y., Mousa S.A., Thoolen M.J., Reilly T.M., DeGrado W.F., Olson R.E., and Wexler R.R. Synthesis and pharmacology of orally active, isoxazoline glycoprotein IIb-IIIa receptor antagonists. 211 ACS Meeting. New Orleans, USA (1996)
101. Mousa S.A., Forsythe M., Lorelli W., Bozarth J., Xue C.-B., Wityak J., Sielecki T.M., Olson R.E., DeGrado W.F., Kapil R., Hussain M., Wexler R.R., Thoolen M.J., and Reilly T.M. Novel non-peptide antiplatelet GPIIb/IIIa receptor antagonist. DMP 754: Receptor binding affinity & specificity. Coronary Artery Disease 7 (1996) 767-774
102. Xue C-B, Wityak J, Sielecki TM, Pinto DJ, Batt DG, Cain GA, Sworin M, Rockwell AL, Roderick JJ, Wang S, Orwat MJ, Frietze WE, Bostrom LL, Liu J, Higley CA, Rankin FW, Tobin AE, Emmett G, Lalka GK, Sze JY, DiMeo SV, Mousa SA, Thoolen MJ, Racanelli AL, Hausner EA, Reilly TM, DeGrado WF, Wexler RR, Olson RE. The discovery of an orally active series of isoxazoline GPIIb/IIIa antagonists. J Med Chem (submitted for publication).
103. (Abstract). Racanelli A.L., Kapil R.P., Mousa S.A., Reilly T.M., and Thoolen M.J. Oral antiplatelet effects of DMP 754 in dogs and non-human primates. Circulation 94 (1996) I-565
104. (suppl.). Himmelsbach F., Austel V., Guth B., Lenz G., Miller T.H., Pieper H., Seewald-Becker E., and Wersenberger H. Design of highly potent nonpeptidic fibrinogen receptor antagonists. Eur J Med Chem 30 (1995) 2435-2445
105. (Abstract 1557). Müller T.H., Schurer H., Waldmann L., Bauer E., Himmelshach F., and Binder K. Oral activity of BIBU 104 a prodrug of the non-peptide fibrinogen receptor antagonist BIBU 52in mice and monkeys. Thromb Haemostasis 69 (1993) 975
106. (Abstract). a) M.T., Weisenberger H., Brickl R., Rühr K., Narjes H., and Himmelsbach F. Anti-aggregatory profile of the platelet glycoprotein (GP) IIb/IIIa antagonist BIBU 52 in ex vivo studies in man. Thromb Haemostas 69 (1995) 1447
107. (Abstract). Müller T.H., Weisenberger H., Brickl R., Kirchner M., Narjes H., Himmelsbach F., Guth B.D., and Krause J. Pharmacodynamics and-Kinetics of BIBU 52 a platelet glycoprotein (GP) IIb/IIIa antagonistand its orally active produg BIBU 104 in man. Thromb Haemostat 69 (1995) 1445
108. (Abstract). Narjes H., Weisenberger H., Müller T.H., Deichsel G., and Krause K. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 in healthy volunteers. Thromb Haemostat 69 (1995) 1315
109. Weiler T., Alig L., Beresini M., Blackburn B., Bunting S., Hadváry P., Müller M.H., Knopp D., Levet-Trafit B., Lipari M.T., Modi N.B., Muller M., Refino C.J., Schmitt M., Schönholzer P., Weiss S., and Steiner B. Orally active fibrinogen receptor antagonists. 2.Amidoximes as prodrugs of amidines. J Med Chem 39 (1996) 3139-3147
110. Scrip 1996; No. 2169,9.
111. Just M., Hropot M., Jablonka B., and König W.; S.HU. Biological characteristics of the new orally active fibrinogen receptor antagonist-S1762. Thrombosis Haemostasis 73 (1995) 1444
112. Stilz H.U., Jablonka B., Just M., Knolle J., Paulus E.F., and Zoller G. Discovery of an orally active non-peptide fibrinogen receptor antagonist. J Med Chem 39 (1996) 2118-2122
113. Kawamura M., Imura Y., Moriya N., Kita S., Fukushi H., Sugihara H., Nishikawa K., and Terashita ZI. Antithrombotic effects of TAK-029an ovel GPIIb/IIIa antagonist in guinea pigs: comparative studies with ticlopidine clopidogrel aspirin prostaglandin E1and argatroban. J Pharmacol Exper Ther 277 (1996) 502-510
114. (Abstract). Brownlie R.P., Brownrigg N.J., Butcher H.M., Garcia R., Jessup R., Lee V.J., Tunstall S., and Wayne MG. ZD2486: a potent and selective antgonist of platelet fibrinogen receptors (glycoprotein IIb/IIIa). Brit J Pharm 117 (1996) 232P
115. Miller W.H., Ku T., Ali F.E., Bondinell W.E., Calvo R.C., Davis L.D., Erhard K.F., Hall L.B., Huffman W.F., Keenan R.M., Kwon C., Newlander K.A., Ross S.T., Samanen J.M., Takata D.T., and Chuan-Kui Y. Enantiospecific synthesis of SB 214857 a potent orally^active nonpeptide fibrinogen receptor antago-nist. Tetrahedron Lett 36 (1996) 9433-9436
116. Scrip Current Awareness - CVS 9/30/96.
117. Demrow H., Batley C., and Folts JD. SDZ GPI 562 an oral peptidomimetic inhibitor of the platelet GpIIb-IIIa abolishes epinephrine shear induced cyclic flow reductions in stenosed monkey carotid arteries. 44th Annual Scientific Session of the American College of Cardiology. New Orleans LA March 19-22. J Am Coll Cardiol (1995) 70A-71A
118. Cook N.S., Bruttger O., Pally C., and Hagenbach A. The effects of two glycoprotein IIb/IIIa antagonists. Ro 43-8857 L-700462 on platelet aggregation and bleeding in guinea-pigs and dogs: Evidence that Ro 43-8857 is orally active. Thromb Haemostas 70 (1993) 838-847
119. Pt. 2. Tcheng JE. Enhancing safety and outcomes with the newer antithrom-botic and antiplatelet agents. Am Heart J 130 3 (1995) 673-679
120. Rodgers R.P.C., and Levin J. A critical reappraisal of the bleeding time. Sem Thromb Haemostas 16 (1990) 1-20
121. (Abstract). Jones C.R., Ambros R.J., Rapold H.J., Steiner B., Weller T., van H.P., Crijins H.J.M.J., Jonkman J.H.G., and Hadváry P. Ro 44-9883: A novel non peptide GPIIb/IIIa antagonist in man. Thromb Haemostas 69 (1993) 560
122. Frelinger I.A., Lam S.-T., Plow E.F., Smith M.A., Loftus J.C., and Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 263 (1988) 12397-12402
123. 3 (glycoprotein IIb-IIIa) alter receptor affinity specificity and function. J Biol Chem 266 (1991) 17106-17111
124. Kouns W.C., Newman P.J., Puckett K.J., Miller A.A., Wall C.D., Fox C.F., Seyer J.M., and Jennings LK. Further characterization of the loop structure of platelet glycoprotein IIIa: Partial mapping of functionally significant glycoprotein IIIa epitopes. Blood 78 (1991) 3215-3223
125. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 19 (1994) 125-134